It appears that your browser may be outdated and performance may be limited. The My Study builder is best viewed with the latest internet browsers. However, if you’d prefer to use our standard form, you can access it below.

Go to Internet Explorer Quick Quote Form

Dismiss this message

Salivary 17 Alpha-OHP

Technical Summary

Analyte Summary
Analyte: 17α-Hydroxyprogesterone
Aliases: 17-OH progesteron, 17OHP
Serum-Saliva Correlation: 0.64
Optimum Collection Volume: 125 μL*
*Add 300 µl to the total volume of all tests for liquid handling
Interfering Factors
Assay Summary
Methodology: ELISA
Sensitivity: 3 pg/mL
Assay Range: 5.1 pg/mL - 500pg/mL
Assay Type: Quantitative

Collect Saliva Samples


Better results begin with better analyte collection. This collection protocol features general considerations to maximize salivary 17OHP analysis. Use this analyte-specific collection protocol to plan your collection methodology and sampling schemes.


Test Saliva Samples

@ Salimetrics
Salimetrics SalivaLab - Easy & Accurate
Order Code (lab): 5147
Transport Requirements: Ship on Dry Ice
@ Your Own Lab
Salimetrics Assay Kits - Better Results

Add DNA Analysis to My Study

Considerations for adding Salivary DNA to analyte Studies:

You can combine salivary analytes with easy, accurate, and affordable genomic testing using Salimetrics SalivaLab and the same sample that you are already collecting – no specialized saliva collection devices or additional samples are required.

Don’t know what SNPs are right for you? The SalivaLab’s DNA team specializes in genetic testing services, we recommend you Request a DNA Consult (gratis) to learn more about common considerations such as # of samples, participant ethnicity, and IRB Approval.

All DNA Services

DNA Extraction and Normalization
Single Nucleotide Polymorphism (SNP) Genotyping
VNTR & STR Analysis

References & Salivary 17OHP Research

    1. Pasquali, R., Patton, L., Pocognoli, P., et al. (2007).  17-Hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.  J Clin Endocrin Metab, 92(11), 4208-17.
    2. Şahin, Y., Keleştimur, F. (1997). 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: Investigation of adrenal and ovarian cytochrome P450c17α dysregulation.  Hum Reprod, 12(5), 910-13.
    3. Strott, C.A., Yoshimi, T., Lipsett, M.B. (1969).  Plasma progesterone and 17-hydroxyprogesterone in normal men and children with congenital adrenal hyperplasia.  J Clin Invest, 48(5), 930-39.
    4. Weliky, I., Engel, L.L. (1962).  Metabolism of progesterone-4-C14 and pregnenolone-7α-H3 by human adrenal tissue.  J Biol Chem, 238(4), 1302-7.
    5. Santos, C.M., Abad, L.R., Cua, S.C. & Domingo, C.F. (2003). Monitoring congenital adrenal hyperplasia using blood spot 17-hydroxyprogesterone assay. Southeast Asian J Trop Med Public Health, 34(Suppl 3), 174-8.
    6. Sack, J., Front, H., Kaiserman, I., Schreiber, M. (1997). 21-hydroxylase deficiency: Screening and incidence in Israel. Horm Res, 48(3), 115-9.
    7. New, M.I., Levine, L.S. (1984). Congenital adrenal hyperplasia. Monographs on Endocrinology, 26, 1-88.
    8. Van der Kamp, H.J, Wit, J.M. (2004). Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol, 151(Suppl. 3), U71-5.
    9. Hughes, I.A., Winter, J.S. (1976).  The application of a serum 17-OH progesterone radioimmunoassay to the diagnosis and management of congenital adrenal hyperplasia. J Pediatrics, 88(5), 766-73.
    10. Gröschl, M., Rauh, M., Dörr, H.-G. (2003).  Circadian rhythm of salivary cortisol, 17α-hydroxyprogesterone, and progesterone in healthy children.  Clin Chem, 49(10), 1688-91.

    1. Goudas, V.T., Dumesic, D.A. (1997). Polycystic ovary syndrome. Endocrinol Metab Clin North Am, 26(4), 893-912.
    2. Vining, R.F., McGinley, R.A. (1987). The measurement of hormones in saliva: Possibilities and pitfalls. J Ster Biochem, 27(1-3), 81-94.

Contact: Salimetrics (USA)
View All International Distributors

Salimetrics’ COVID-19 Status – 8 April 2020 – No change to Prior Update:

Salimetrics’ Sales and Customer Service, as well as all other non-laboratory personnel, have successfully transitioned to working remote and are fully able to provide support to our customers.

Our Salimetrics Pennsylvania Manufacturing Center remains open for customer orders and shipments. All Salimetrics’ laboratory personnel are following PPE guidelines per CDC Biosafety Level 2 (BSL-2).

The Salimetrics’ SalivaLab, located in California, is open to receive samples. In accordance with State of California Executive Order N-33-20 effective March 19, 2020, our Carlsbad, California facility, including R&D and SalivaLab personnel, will remain open working on research critical to the COVID-19 response; onsite SalivaLab personnel will be able to receive samples, and in some cases, test and send data.  All Salimetrics’ laboratory personnel are following PPE guidelines per CDC Biosafety Level 2 (BSL-2).



COVID-19 Notice